BioNTech said that its VEGF bispecific sets it apart from competitors because of its mechanism and how it plans to ...

Arcus Biosciences (RCUS) announced results from Part 1 of ARC-10, a randomized, open-label, three-arm study evaluating domvanalimab, an ...

A new analysis of real-world data show that just as in solid tumors, higher tumor mutational burden (TMB) and PD-L1 expression in blood cancers are linked to less-optimistic prognoses.

(RTTNews) - Arcus Biosciences, Inc. (RCUS), Tuesday announced results from part 1 of ARC-10, evaluating the effects of the combination of Domvanalimab and Zimberelimab versus Zimberelimab or ...

Q3 2024 Earnings Call Transcript November 4, 2024 Operator: Welcome to BioNTech’s Third Quarter 2024 Earnings Call. I would like to hand the call over to Michael Horowicz, Director of Investor ...

The following is a summary of "Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and ...

Despite the PDUFA date being extended by three months for Merus’ zenocutuzumab, Truist Securities analyst Asthika ...

Ugur Sahin; Chief Executive Officer, Member of the Management Board; Biontech SE Oezlem Tuereci; Chief Medical Office, Member of the Management Board; Biontech SE Welcome to BioNTech's third quarter ...

INBX's two main pipeline candidates are entering critical late-stage trials with data readouts expected in mid- to late-2025. Click here to read my analysis.

Israeli researchers believe they've found a way of identifying and removing senescent cells by adapting a new generation of ...

Three phase 3 trials of combinations including datopotamab deruxtecan for the treatment of non–small cell lung cancer are beginning.

Driven by the early approval of its updated COVID-19 vaccine, BioNTech far exceeded analysts’ expectations in the third ...